85P Efficacy and safety of dostarlimab plus carboplatin–paclitaxel in first-line patients with mismatch repair-deficient or microsatellite instability-high recurrent or primary advanced endometrial cancer: An italian real life experience

Endometrial cancer (EC) is one of the most common gynaecological cancers with an increased incidence (1). Based on the RUBY phase III clinical trial dostarlimab plus carboplatin–paclitaxel significantly increased progression-free survival (PFS) among patients with primary advanced or recurrent EC, with a substantial benefit in the dMMR/MSI-H population (2).